Compare Alphabet Inc Class A (GOOGL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Tango Therapeutics Inc. — how do they compare? Alphabet Inc Class A trades at $342.19 (market cap $4.30T), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Alphabet Inc Class A is far larger — about 1146.7× Tango Therapeutics Inc.'s market cap, and Alphabet Inc Class A pays a 0.25% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 86 Days and Tango Therapeutics Inc. for 0 Days on average.
| GOOGL | TNGX | |
|---|---|---|
Market Cap | $4.30T | $3.75B |
Volume | 22,270,289 | 9,619,106 |
Sector | Media | Health |
52-Week High | $402.62 | $32.90 |
52-Week Low | $250.46 | $7.50 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $4.19T | $2.77B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $347.64, down 1.44% today, but maintains strong technical support near $344-$350. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 54.77% net margin. Recent earnings beats and strong analyst consensus support the bullish outlook, with 87% of analysts rating it a Buy. Technical indicators show bullish moving averages but overbought RSI conditions.
Alphabet presents a compelling investment case with strong AI-driven growth, consistent earnings outperformance, and dominant market positioning. Key risks include regulatory scrutiny, competitive pressures in AI, and market volatility. With a consensus price target of $430.96 representing 24% upside potential, the stock offers attractive long-term value despite short-term technical overbought conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
